Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial. Harding, J. J., Piha-Paul, S., Shah, R. H., Cleary, J. M., Quinn, D. I., Brana, I., Moreno, V., Borad, M. J., Loi, S., Spanggaard, I., Ford, J. M., DiPrimeo, D., Berger, M. F., Eli, L., Meric-Bernstam, F., Solit, D. B., Abou-Alfa, G. K. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680301245